Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Similar articles for PubMed (Select 24557436)

1.

Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer.

Acevedo-Gadea C, Santin AD, Higgins SA, Urva S, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Abu-Khalaf MM.

Int J Gynecol Cancer. 2014 Mar;24(3):528-33. doi: 10.1097/IGC.0000000000000085.

PMID:
24557436
2.

A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.

Temkin SM, Yamada SD, Fleming GF.

Gynecol Oncol. 2010 Jun;117(3):473-6. doi: 10.1016/j.ygyno.2010.02.022. Epub 2010 Mar 28.

PMID:
20347480
3.

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.

Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM, Wolf J.

Cancer. 2010 Dec 1;116(23):5415-9. doi: 10.1002/cncr.25515. Epub 2010 Aug 2.

4.

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.

Deenen MJ, Kl├╝mpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, Schellens JH, Wilmink JW.

Invest New Drugs. 2012 Aug;30(4):1557-65. doi: 10.1007/s10637-011-9723-4. Epub 2011 Aug 2.

5.

Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.

Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, Lu KH, Coleman RL.

J Clin Oncol. 2015 Mar 10;33(8):930-6. doi: 10.1200/JCO.2014.58.3401. Epub 2015 Jan 26.

PMID:
25624430
6.

A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.

Fury MG, Sherman E, Haque S, Korte S, Lisa D, Shen R, Wu N, Pfister D.

Cancer Chemother Pharmacol. 2012 Mar;69(3):591-8. doi: 10.1007/s00280-011-1734-5. Epub 2011 Sep 13.

PMID:
21913034
7.

A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.

Mok TS, Wong H, Zee B, Yu KH, Leung TW, Lee TW, Yim A, Chan AT, Yeo W, Chak K, Johnson P.

Cancer. 2002 Oct 1;95(7):1511-9.

8.

Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature.

Traina TA, Sabbatini P, Aghajanian C, Dupont J.

Gynecol Oncol. 2004 Oct;95(1):235-41. Review.

PMID:
15385138
9.

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.

Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE.

Cancer. 2011 Sep 15;117(18):4194-200. doi: 10.1002/cncr.25931. Epub 2011 Mar 8.

10.

RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.

Chinnaiyan P, Won M, Wen PY, Rojiani AM, Wendland M, Dipetrillo TA, Corn BW, Mehta MP.

Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):880-4. doi: 10.1016/j.ijrobp.2013.04.036. Epub 2013 May 29.

11.

Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study.

Joka M, Boeck S, Zech CJ, Seufferlein T, Wichert Gv, Licht T, Krause A, Jauch KW, Heinemann V, Bruns CJ.

Anticancer Drugs. 2014 Oct;25(9):1095-101. doi: 10.1097/CAD.0000000000000146.

PMID:
25029236
12.

A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.

Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D, Skarin A, Eder JP Jr.

Clin Cancer Res. 2002 Mar;8(3):691-7.

13.

A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.

Agelaki S, Kontopodis E, Kotsakis A, Chandrinos V, Bompolaki I, Zafeiriou Z, Papadimitraki E, Stoltidis D, Kalbakis K, Georgoulias V.

Cancer Chemother Pharmacol. 2013 Jul;72(1):45-51. doi: 10.1007/s00280-013-2167-0. Epub 2013 Apr 21.

PMID:
23604531
14.

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.

Ramalingam SS, Harvey RD, Saba N, Owonikoko TK, Kauh J, Shin DM, Sun SY, Strychor S, Tighiouart M, Egorin MJ, Fu H, Khuri FR.

Cancer. 2010 Aug 15;116(16):3903-9. doi: 10.1002/cncr.25264.

15.

Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.

Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL, Egorin MJ, Schilsky RL, Ratain MJ.

J Clin Oncol. 1998 Oct;16(10):3302-9.

PMID:
9779705
16.

Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.

Miller AA, Al Omari A, Murry DJ, Case D.

Lung Cancer. 2006 Dec;54(3):379-85. Epub 2006 Oct 16.

PMID:
17049403
17.

A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.

Rose PG, Sill MW, McMeekin DS, Ahmed A, Salani R, Yamada SD, Wolfson AH, Fusco N, Fracasso PM.

Gynecol Oncol. 2012 Apr;125(1):158-62. doi: 10.1016/j.ygyno.2011.12.431. Epub 2011 Dec 22.

PMID:
22198338
18.

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.

Jerusalem G, Fasolo A, Dieras V, Cardoso F, Bergh J, Vittori L, Zhang Y, Massacesi C, Sahmoud T, Gianni L.

Breast Cancer Res Treat. 2011 Jan;125(2):447-55. doi: 10.1007/s10549-010-1260-x. Epub 2010 Nov 25.

PMID:
21107682
19.

A phase I-II trial of weekly topotecan in the treatment of recurrent cervical carcinoma.

Puls LE, Phillips B, Schammel C, Hunter JE, Griffin D.

Med Oncol. 2010 Jun;27(2):368-72. doi: 10.1007/s12032-009-9219-7. Epub 2009 Apr 21.

PMID:
19381891
20.

Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.

Gadgeel SM, Lew DL, Synold TW, LoRusso P, Chung V, Christensen SD, Smith DC, Kingsbury L, Hoering A, Kurzrock R.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1089-96. doi: 10.1007/s00280-013-2297-4. Epub 2013 Sep 22.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk